Parascript Granted Patents for Technology Offering Greater Accuracy in Assessing Mammograms

November 15, 2012, Longmont, CO – Parascript®, LLC, the image analysis and pattern recognition technology provider, today announced that the United States Patent and Trademark Office has granted two patents for its technology that provides improvements in detecting suspicious lesions on mammograms when utilizing computer-aided detection (CAD) software.

Parascript was granted U.S. Patent No. 8,311,296 for “Voting in Mammography Processing” this month. It also recently received U.S. Patent 8,194,965 for “Method and system of providing a probability distribution to aid the detection of tumors in mammogram images”. These technologies are utilized in Parascript’s CAD software, AccuDetect®.

AccuDetect integrates with existing full-field digital mammography (FFDM) or computed radiography (CR) digital CAD systems.  The technology automatically analyzes digital mammography images to identify suspicious areas for possible soft tissue densities and/or calcifications and enables a more accurate interpretation of mammograms. It is used to identify and highlight hard-to-find lesions and anomalies on medical images that may be indicative of cancer and bring them to the attention of radiologists.

Parascript’s patent, “Voting in Mammography Processing”, protects the company’s unique approach to achieving high performance in AccuDetect. Complementary algorithms are used to detect the presence of suspicious lesions on mammography images.  Parascript then applies proprietary technology to arrive at final detection results, based on the analysis of the detection results from each algorithm. The voting technology has served as an important component in creating a CAD product with high sensitivity and low false-positive rates.

Parascript’s patent, “Method and system of providing a probability distribution to aid the detection of tumors in mammogram images”, protects the technology provider’s unique ability to apply an advanced mathematical model called Conditional Random Field to significantly improve the quality of cancer detection.

 “Our long-term goal is to create a CAD product which will match the performance of the most experienced radiologists. To achieve this goal we need to create significantly more sophisticated technology compared to that traditionally utilized in CAD products. These two patents represent an important step in this direction. The technology protected by these patents has enabled AccuDetect to achieve both high sensitivity and low false-positive rates,” said Alexander Filatov, president at Parascript.

Parascript’s AccuDetect technology has been successfully deployed in Austria, France, Germany, Italy, The Netherlands and Sweden. It will be on display at booth #4650 at the Radiological Society of North America’s (RSNA) annual conference at McCormick Place, Chicago from November 25-30.

For more information about voting in CAD for Mammography, please see Parascript’s white paper.


About Parascript, LLC

Parascript is a leading developer of cursive, handprint, and machine print recognition technology. Leveraging digital image analysis and advanced pattern recognition, its software enables business automation in areas like forms processing, postal and financial automation, and fraud prevention; and supports cancer screening in medical imaging. Parascript’s award-winning technology draws on a proven 15+ year track record and processes billions of document images annually. Fortune 500 companies, postal operators (including the U.S. Postal Service), major government and financial institutions rely on Parascript products, which are distributed through its partner network, including: IBM, EMC, Bell and Howell, Fiserv, Selex Elsag, Lockheed Martin, NCR, Siemens, and Burroughs. Visit Parascript online at